SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021)
SAB Biotherapeutics (SABS) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $116.2 million as the latest value for Q3 2021.
SAB Biotherapeutics (SABS) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $116.2 million as the latest value for Q3 2021.
| Date | Value |
|---|---|
Offer Ends In
Starting from $49 $19 / month